The ability of pGCD59 to predict adverse pregnancy outcomes: a prospective study of non-diabetic pregnant women in Ireland.

"Declarations Conflict of interestJAH has a financial interest in Mellitus LLC. Mellitus has licensed intellectual property for the technology used in this research and in developing diagnostic tools for diabetes. The interests of J.A.H. are reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. Reagents and laboratory analysis for pGCD59 were provided by Prof Jose A. Halperin. Ethical approvalEthical approval for this study was granted by the Clinical Research Ethics Committee, Galway, Ireland (Reference No- C.A. 2026). Informed consentInformed consent was obtained from all participants in this study. Conflict of interest JAH has a financial interest in Mellitus LLC. Mellitus has licensed intellectual property for the technology used in this research and in developing diagnostic tools for diabetes. The interests of J.A.H. are reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. Reagents and laboratory analysis for pGCD59 were provided by Prof Jose A. Halperin. "

"Funding This work was performed within the Irish Clinical Academic Training (ICAT) Programme (www.icatprogramme.org), supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z) the Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. The funding source had no role in the study design, analysis, or writing of report. DB is employed as an ICAT fellow, National Institutes of Health Grant DK095424 (JAH), DK62294 (JAH), DK089206 (JAH), DK101442 (JAH)."